Therapy Dog Provides Greater Service: Helping Define Osteosarcoma Treatment
Denali, a therapy dog, inspires patients in hospitals, but is also an inspiration himself. Diagnosed with osteosarcoma, Denali is part of an ongoing clinical study using the ADXS-cHER2 immunotherapy (AT-014). The study is being conducted at the University Of Pennsylvania School Of Veterinary Medicine by Dr. Nicola Mason. Watch the news story from the CBS affiliate in New York City.
The current standard of care for dogs with osteosarcoma is amputation of the affected leg followed with chemotherapy. Some dogs are not good candidates for limb amputation, however, and these dogs are treated with palliative radiation therapy, which helps to reduce the pain associated with the tumor. Denali is participating in a study that examines whether the addition of ADXS-cHER2 immunotherapy to radiation therapy helps to prolong survival of these dogs. This study is currently enrolling participants.
An earlier clinical study examined ADXS-cHER2 immunotherapy (AT-014) in 21 client-owned dogs with osteosarcoma. In this study, dogs were treated with ADXS-cHER2 immunotherapy after the standard of care (amputation and follow up chemotherapy). So far, there has been a statistically significant prolonged overall survival benefit (p = 0.003) compared with dogs that received standard of care without ADXS-cHER2. The median survival time for dogs that did not receive ADXS-cHER2 immunotherapy was eight months, whereas the median survival time for those dogs treated with ADXS-cHER2 has not yet been reached. There were no short- or long-term complications associated with the immunotherapy and only low-grade, transient toxicities were reported in the study.